Navigation Links
More Than 300 New Medicines Being Developed for Mental Illnesses
Date:7/24/2008

NEW ORLEANS, July 24 /PRNewswire-USNewswire/ -- There are a record 301 new medicines being developed for mental illnesses, according to a new report released here today during a briefing that focused on the devastating effects that mental illnesses have on patients, their families, and society. Nationwide, mental illness affects nearly 60 million American adults. The briefing, led by the Pharmaceutical Research and Manufacturers of America (PhRMA), featured Emmy Award-winning actor Joey Pantoliano -- well known for his role in The Sopranos -- who suffers from depression.

In Louisiana, rates of post-traumatic stress disorder and suicide have increased since hurricanes Katrina and Rita, according to the National Institute on Drug Abuse. Mental disorders after a natural disaster usually decrease with time, with about 50 percent of post-traumatic mental disorders resolved within a year of the disaster, notes a recent Harvard University study. However, in the case of Hurricane Katrina, the researchers found the contrary: Anxiety or mood disorder has been increasing by 30 percent and more.

"We are releasing this report in Louisiana in view of the upcoming third anniversary of Hurricane Katrina and the state's continuing need for assistance in treating mental illness," said PhRMA Senior Vice President Ken Johnson. "The medicines being developed treat a range of conditions, from depression to anxiety, and from schizophrenia to dependence on alcohol and drugs. These medicines are either in clinical trials or awaiting review by the U.S. Food and Drug Administration, and they will help patients live longer, happier, and healthier lives. It's important for patients and healthcare providers to know that research into mental illness remains a top priority."

Many of these diseases, such as depression, were once misunderstood causes of shame and fear. Fortunately, today many are highly treatable conditions.

Unfortunately, despite the tremendous pr
'/>"/>

SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
2. European Medicines Agency Adopts Positive Opinion for Ranolazine for Treatment of Chronic Angina
3. Report on 750 New Medicines in Development for Cancer Released in Baton Rouge
4. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
5. ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication
6. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
7. New Report Offers Hope for Closing Health Gap for African Americans, With Nearly 700 Medicines in Pipeline
8. 92 Medicines and Vaccines now in Development for HIV/AIDS
9. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
10. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
11. Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)...October 7 /-,Sosei Group Co...ectura,Group plc ("Vectura"; LSE: VEC), announce r...cacy, safety and tolerability of NVA237 presented ... Society (ERS) in Berlin,Germany. The new data sh...nhaled long-acting muscarinic antagonist (LAMA), p...
(Date:10/6/2008)...wswire/ -- "A return to the use of,chimpanzees in ...cientific,justification," according to a paper rel...ory Animals (ATLA). "An Assessment of the Role of,...at vaccine responses in,chimpanzees are not predic...impanzees, critical role and importance in AIDS va...
(Date:10/6/2008)... children, parents discussing clinical ...6 /PRNewswire-USNewswire/ -- From asthma and cance...es lives and improves their,health and well-being....alth (NIH), "Children and Clinical Studies", (http... offers parents and health,care providers an insid...
(Date:10/6/2008)...with Durezol Dosed Prior to Surgery, TAMPA, Fla.,... a,privately held ophthalmic-focused biopharmaceut...fluprednate ophthalmic emulsion) 0.05% is now,comm... the U.S. Food and,Drug Administration in June 200...d for the treatment of inflammation and pain assoc...
Breaking Medicine Technology:NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5Research Attributes Lack of HIV/AIDS Vaccine to Use of Chimpanzees 2Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 2Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 3Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 2Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 5VioQuest Pharmaceuticals Inc Valuation Upgrade Review Issued By Scimitar Equity LLC 6779 1VioQuest Pharmaceuticals Inc Valuation Upgrade Review Issued By Scimitar Equity LLC 6779 2Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony 28TM 29 Transdermal Continuous Glucose Monitoring System in Patients 2729 1Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony 28TM 29 Transdermal Continuous Glucose Monitoring System in Patients 2729 2Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony 28TM 29 Transdermal Continuous Glucose Monitoring System in Patients 2729 3Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony 28TM 29 Transdermal Continuous Glucose Monitoring System in Patients 2729 4Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results 6772 1Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results 6772 2Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results 6772 3Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results 6772 4Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results 6772 5Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results 6772 6Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results 6772 7CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011 vcMMAE 2728 1CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011 vcMMAE 2728 2CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011 vcMMAE 2728 3CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011 vcMMAE 2728 4CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011 vcMMAE 2728 5
...WIRE)--Jul 2, 2007 - ViaCell, Inc.,(NASDAQ: VIAC) ...hief Executive Officer of ViaCell, will present an...eline at the C.E. Unterberg,Towbin Emerging Growt...07 at 3:00 p.m. at the Mandarin Oriental Hotel in ...tion will be available on,the Investor Information...
..., July 10, 2007 /CNW/ - Protox,Therapeutics Inc. (...lts from its Phase 1 clinical trial evaluating ,PR...e cancer,following radiation failure. The trial r...rated and shows promising signs,of therapeutic act...t. , ,"The completion of the PRX302 Phase 1 ...
Other Medicine Technology:Protox Announces Positive Clinical Data from Prostate Cancer Study 2Protox Announces Positive Clinical Data from Prostate Cancer Study 3Protox Announces Positive Clinical Data from Prostate Cancer Study 4Protox Announces Positive Clinical Data from Prostate Cancer Study 5
(Date:10/7/2008)...RNewswire-FirstCall/ -- Stallergenes S.A.,today an...greement with,Catalent for the promotion and distr...FLEX(R), co-developed and co-manufactured by Catal...sts of a syringe pre-filled with adrenaline, which....3 and 0.15 mg), in an,autoinjector device. The Me...
(Date:10/7/2008)...of asthma in a young child may well be more challe..., according to a review of research and clinical e... Indiana University School of Medicine and Riley H... issue of Clinical Pediatrics . , "Wheezing ca... Professor of Pediatrics at the IU School of Medic...
(Date:10/7/2008)...rial Specialties, Mfg. is pleased to announce the ...hese filters are exclusively available from Indust... push-to-connect style fittings integrated into th...ne filter offers versatility and customization for... (PRWEB) October 7, 2008 -- Exclusively availa...
(Date:10/6/2008)...fight against childhood obesity, researcher notes ... Three-quarters of middle schools have vending mac...new study finds. , The research demonstrates th...ls, and "that those vending machines don,t always ...y Virus, a registered dietitian with the Center fo...
Breaking Medicine News(10 mins):Health News:Stallergenes Partners With Catalent and the Medical House for Commercialization of Adrenaline Autoinjector in Europe 2Health News:Wheezing and asthma in young children 2Health News:Vending Machines Found in Most Middle Schools 2
India, Pakistan Teams To Inaugurate Inzy's Hospital
... been found through an animal study that Aspartame...ut that drinking four to five 20-ounce bottles of ...be the //cause of cancers. The study would be pub...ironmental Health Perspectives, an US government-r...
...East Asia has been long considered a wonderland fo...otel lobbies or restaurants without any inhibition...vernment is seriously thinking about imposing a sm...bars. In Malaysia and Thailand, smoking bans alre...
...attempting to learn a new task, taking short break...easy, according to a new study conducted by Massac...d Foster and Matthew Wilson, working at the Massac...bridge, found that rats' brains 'replay' their exp...
Other Medicine News:Health News:Smoking Ban To Be Soon Implemented In South East Asian Bars 2Health News:Task Learning Made Simple By Taking Short Breaks 2
Lorenz 2.0 mm titanium system for the midface provides an excellent alternative to lower profile systems in areas of the midface where greater fixation is needed.
The Neuroclip is designed for safe, quick, and stable fixation of cranial bone flaps. Application is simple with minimal instrumentation. The Neuroclip can be applied to the cranial bone flap while t
Lorenz 1.0 mm titanium system provides a rigid fixation alternative for areas with high palpability and prominent bone formation. These areas include the frontal bone and the areas surrounding the or
1.0 mm Micro System. The Titanium Micro System is also useful in the practice of ENT, Neurosurgery and Handsurgery.
Medicine Products: